Chan T M, Cheng I K, Wong K L, Chan K W, Lai C L
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
Am J Nephrol. 1991;11(6):493-6. doi: 10.1159/000168366.
A patient who developed crescentic IgA nephropathy following treatment with recombinant interleukin-2 (rIL2) and lymphokine-activated killer (LAK) cell therapy for hepatocellular carcinoma was reported. Cessation of rIL2 and LAK cell treatment plus plasmapheresis and steroid therapy was successful in achieving partial improvement and stabilization of renal function. This is the first case report of biopsy-documented glomerulonephritis developing after IL2 and LAK cell therapy. This provides indirect in vivo evidence for the role of IL2 in mediating glomerular injury in IgA nephropathy.
据报道，一名肝细胞癌患者在接受重组白细胞介素-2（rIL2）和淋巴因子激活的杀伤细胞（LAK）治疗后发生了新月体性IgA肾病。停用rIL2和LAK细胞治疗，加上血浆置换和类固醇治疗，成功实现了肾功能的部分改善和稳定。这是第一例有活检记录的在IL2和LAK细胞治疗后发生肾小球肾炎的病例报告。这为IL2在介导IgA肾病肾小球损伤中的作用提供了间接的体内证据。
